Sleep medicine has a growing evidence base. Interventions that were once dismissed as placebo — cognitive behavioral therapy for insomnia, light therapy, temperature manipulation — have been validated in randomized controlled trials. And interventions that feel helpful — high-dose melatonin, Benadryl, cannabis — often produce worse long-term outcomes than they prevent. Here is the evidence-based hierarchy.
Tier 1: Strongest Evidence
Cognitive Behavioral Therapy for Insomnia (CBT-I) has more evidence for long-term insomnia treatment than any other intervention — including sleep medications. A 2015 meta-analysis in Annals of Internal Medicine found CBT-I superior to pharmacotherapy for chronic insomnia on every long-term outcome measure. CBT-I components include sleep restriction therapy (temporarily limiting time in bed to consolidate sleep), stimulus control (associating the bed only with sleep), sleep hygiene optimization, and cognitive restructuring of anxiety-producing sleep beliefs. Available through therapists, apps (Sleepio, Insomnia Coach), and online programs.
Light therapy for circadian disruption is supported by multiple RCTs. Morning bright light (10,000 lux for 20–30 minutes) effectively advances circadian phase — making it the most appropriate treatment for delayed sleep phase disorder and social jet lag. Evening light restriction is the necessary complement — blocking circadian phase delay caused by artificial light exposure.
Temperature manipulation: Sleep onset requires a 1–2°C drop in core body temperature. Sleeping in a cool environment (65–68°F) facilitates this drop and consistently improves slow-wave sleep in controlled studies. Active cooling technology (Eight Sleep, ChiliPad) shows particularly impressive results in objective sleep studies — increasing deep sleep time by 10–30 minutes per night in many users.
Tier 2: Strong Evidence for Specific Applications
Magnesium glycinate (300–400 mg at bedtime): Magnesium is cofactor for GABA synthesis and serves as a physiological calcium channel blocker, reducing CNS excitability. A deficiency state — common in adults — is associated with poor sleep quality and increased cortisol. Supplementation in deficient individuals improves sleep onset, reduces cortisol, and improves subjective sleep quality. Effect is modest in non-deficient individuals.
Low-dose melatonin (0.5–1 mg, 2–3 hours before target sleep time): Effective for circadian phase-shifting — not as a sedative. This is the evidence-based application. High-dose melatonin (5–10 mg at bedtime) produces sedation but does not correct the underlying circadian issue and often causes morning grogginess.
Phosphatidylserine (300–400 mg): Reduces cortisol release in response to stress, supporting evening cortisol decline. Modest but consistent evidence for improved sleep in individuals with elevated evening cortisol.
The Hormonal Foundation
No behavioral sleep protocol will fully compensate for hormonal deficiency. Declining progesterone, estrogen fluctuations, low testosterone, and thyroid dysfunction all impair sleep architecture through mechanisms that behavioral interventions cannot overcome. For patients whose sleep disruption began during a clear hormonal transition — perimenopause, andropause, thyroid disease onset — hormonal evaluation and optimization is a prerequisite for effective sleep treatment, not an optional add-on.